Rockville, MD. Rise Therapeutics, a synthetic biology drug development company creating targeted immunological-based biologics using a unique and proprietary oral delivery platform, is pleased to announce the expansion of their executive leadership team. Rise welcomes Christian Furlan Freguia, Ph.D., to the position of Vice President of Research.
Dr. Freguia brings over a decade of experience in the biotechnology sector with a successful track record in developing new drugs and translating programs into human clinical trials. Previously, he served as Director of Research at Synthetic Biologics, where he led the discovery and development activities around novel oral biologic drugs, now in clinical trials, and cancer drugs, which resulted in several successful IND filings with the FDA. Dr. Furlan Freguia also invented several new technologies, some of which resulted in the founding of microbiome-based companies.
“Christian’s scientific and entrepreneurial background will contribute significantly to our organization as we continue to advance our mission to develop and launch targeted immunological-based biologics for the treatment of inflammation, autoimmunity, and cancer,” said Dr. Gary Fanger, CEO and President of Rise Therapeutics.
“I am looking forward to contributing to the development of oral synthetic biology-based medicine at Rise,” said Christian. “I look forward to bringing my experience and insights in drug development and my expertise translating programs into human proof-of concept clinical trials to Rise and working alongside these industry leaders to develop novel, first-in-class therapeutics.”
Dr. Furlan Freguia has authored more than 15 articles, and he is an inventor on several patents. He holds a PhD in molecular biology and biochemistry from the University of Ferrara (Italy).
About Rise Therapeutics
Rise Therapeutics is a privately held biotechnology company located in Rockville, Maryland. Rise is pioneering synthetic biology methodologies to develop novel cellular-based medicines. Rise Therapeutics leverages its unique and proprietary TriPartite X (TPX) approach to deliver targeted biologics orally, a novel step forward in the context of protein-based medicines. As a platform drug delivery approach, TPX is ideally suited to deliver any biological therapy orally and, in the context of Rise’s therapeutics product development interests, targeting immunology regulated by the gut microbiome is a key breakthrough that gives Rise a competitive drug development advantage. Rise is currently focused on developing treatments for autoimmunity, inflammatory disease, infection, and cancer. These disease areas represent a large unmet need, both in the United States and around the world. For more information about Rise Therapeutics, please visit www.risetherapeutics.com.